1 May 2005 in European Journal of Cardio-Thoracic Surgery
Objective: After transluminal endovascular implantation of a new valved stent, the aim of this study was to evaluate the feasibility of using a high-pressure water stream to endovascularly resect human calcified aortic valves. Methods: First, human calcified aortic valves were excised and then resected in vitro to determine optimal water jet parameters. Second, healthy porcine aortic valves were ablated in vitro to evaluate possible destruction to the surrounding anatomy. Third, resection was performed endoluminally by introducing microsystemic tools into the descending aorta, passing them through the arch and ascending aorta to the aortic valve in an in vitro porcine model. Macro- and micropathology of specimens were analyzed. Results: First, resection of human calcified valves took a mean of 6.0±2.4min per three leaflets at 150bar (n=17). The maximum size of the cut leaflets was 7.1±1.7mm. Second, resection of healthy porcine aortic valves at 60bar took 2.3±0.3min per three leaflets (n=10). Only the aortic annulus was moderately affected in six cases. Third, endoluminal resection via the descending aorta took 12.2±0.8min per three leaflets at 60bar (n=10). The aortic wall was affected in four cases, the aortic annulus and the coronary ostia only once. Microscopic analysis also revealed superficial lesions with a maximum lesion depth of 1200μm in one case, and an average of 580±145μm in subsequent lesions. The mitral valve and the left ventricular outflow tract were not affected. Conclusions: Percutaneous resection of heart valves is emerging as a promising auxiliary method for the resection of calcified aortic heart valves because they can be cut endoscopically. Nonetheless, before this resection tool can be clinically applied by surgeons to perform a true percutaneous valve replacement, an additional aortic valve resection chamber (already at the prototype stage) designed for capturing all debris, has to be established.
30 September 2005 in The Annals of Thoracic Surgery
1 September 2008 in European Journal of Cardio-Thoracic Surgery
A chronic type A dissection was observed in a 56-year-old woman during a diagnostic CT imaging (Fig. 1A–C ). Typical pain occurred more than 5 years ago. Intraoperatively, a pale thrombus was found and removed (Fig. 1D–E). The operation was successfully performed and the patient was discharged after 10 days.
1 January 2008 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
To improve the outcome of percutaneous valve replacement in aortic stenosis endovascular resection of calcified aortic valves will be necessary. In this study different sealing methods were evaluated. The focus of this research was feasibility and mechanical functionality in human anatomy. The aortic valve isolation chamber (AVIC) is a catheter-based system to seal the aortic valve during resection, and was installed antegrade and retrograde. Firstly, AVIC was inserted antegrade via the cardiac apex in human postmortem models (n = 2), and secondly in porcine in vivo models under extra corporeal circulation (n = 5). Endoscopic inspection of the valve was recorded. AVIC was installed via a port system through the descending aorta. Micro- and macropathologies were performed. AVIC transapical deployment in the two human models took 3 and 4 minutes respectively and 2.2 ± 1.3 minutes in average in the porcine model. From the descending aorta, the deployment took 9.3 ± 5.5 minutes. Fluoroscopy and macroscopy demonstrated sealed chambers. Microscopic and histologic analysis demonstrated no profound damages of the surrounding tissue. This study demonstrates the feasibility of transapical and retrograde endovascular sealing of the aortic valve in vitro and in vivo in nonbeating hearts.
1 August 2007 in European Journal of Cardio-Thoracic Surgery
First, we would like to congratulate Flecher et al. [1] for their work—an important contribution to basic research on percutaneous aortic valve technologies. Unfortunately, interest on basic research in this field seems to have decreased since the human clinical trials began. But despite the clinical accomplishment of percutaneous valve technologies in the last 5 years, many problems are yet unsolved [2].